**Question:** All are true statements regarding octreotide except:

A. Octreotide is a synthetic analogue of the gastrointestinal polypeptide somatostatin.
B. Octreotide has significant affinity for somatostatin receptors 2 and 5.
C. Octreotide is used in the treatment of acromegaly.
D. Octreotide is not absorbed systemically after subcutaneous administration.

**Core Concept:**
Octreotide is a synthetic analogue of the gastrointestinal polypeptide somatostatin. It has significant affinity for somatostatin receptors 2 and 5. These receptors are part of a family of G-protein coupled receptors that regulate various physiological processes, including growth hormone release, gastric acid secretion, and insulin secretion. Octreotide is a potent inhibitor of these processes, making it useful in clinical scenarios involving excessive hormone secretion or abnormal gastrointestinal motility.

**Why the Correct Answer is Right:**
C. Octreotide is used in the treatment of acromegaly (hyperprolactinemia) is incorrect because octreotide primarily targets somatostatin receptors involved in regulating hormone secretion rather than acromegaly itself. Acromegaly is typically treated with medications targeting growth hormone (GH) and its receptor directly, such as pegvisomant or somatostatin analogues like lanreotide.

D. Octreotide is not absorbed systemically after subcutaneous administration is incorrect as octreotide is a synthetic analogue of somatostatin, designed to target somatostatin receptors. Although its bioavailability can be influenced by various factors like subcutaneous injection site or patient factors, octreotide is absorbed systemically.

**Why Each Wrong Option is Incorrect:**
A. Octreotide is a somatostatin analogue, not a gastrointestinal polypeptide. While somatostatin is a gastrointestinal polypeptide, octreotide is a synthetic analogue designed to mimic its actions. This distinction is important because somatostatin is a naturally occurring hormone, while octreotide is a pharmaceutical intervention.

**Clinical Pearl:**
Gastrointestinal motility disorders are often managed with octreotide, specifically targeting somatostatin receptors involved in regulating gastrointestinal smooth muscle contraction and relaxation. This makes octreotide a valuable tool for managing conditions like acute abdomen, acromegaly, and certain forms of diarrhea.